Fast Automated Multiplex Analysis of Neonatal Sepsis Markers on a Centrifugal Mi...
Fast Automated Multiplex Analysis of Neonatal Sepsis Markers on a Centrifugal Microfluidic Platform
The global frequency of neonatal sepsis is 1-21 newborns per 1000 live births with mortality rates as high as 35-70%, amounting to 100,000s of annual cases. The consortium has identified a real and pressing need for increasing dia...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
The global frequency of neonatal sepsis is 1-21 newborns per 1000 live births with mortality rates as high as 35-70%, amounting to 100,000s of annual cases. The consortium has identified a real and pressing need for increasing diagnostic efficacy in a setting that imposes a dramatic healthcare burden on EU (and global) healthcare management systems. The goal of this project is the realization and clinical validation of a fully integrated and automated platform for the parallel detection of neonatal sepsis markers and a panel of sepsis-causing bacteria from a clinical sample (whole blood, cerebrospinal fluid, fluid from joint aspirations or urine). For the first time, this will allow a fast (90 minutes) automated routine diagnosis of neonatal sepsis, permitting a timely and especially specific treatment.
The project has the potential to significantly reduce neonatal mortality and ensure appropriate treatment for one of the most vulnerable patient cohorts in the medical setting: newborns. The interaction between presence of microbial pathogens and the host (patient) response will be investigated in a clinical validation phase with a view to planning patient management more appropriately. In the long term this will also reduce the spread of multiresistant strains emerging from the unspecific use of broad-spectrum antibiotics.
ASCMicroPlat will cover the complete value chain from research and development to clinical validation. The system will be based on the centrifugal microfluidic platform of HSG-IMIT and an inventive foil-technology for the disposable test carriers, which is scalable to industrial production. ASCMicroPlat will enable a sepsis diagnosis based on a sample in – result out process. Additionally, the know-how generated in this project will provide innovative European SMEs with a platform for the fast implementation of lab-on-a-chip tests. The consortium has a strong industrial component including 2 SMEs.